DFX Intelligence
Data Factory
Reading the graph
Reading the graph
| Class | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | ||||||||
| · probable Middle market | New York, | $3.1B | 9 | 8 | 2020 | |||
| · probable | San Francisco, | $89.2M | 4 | 3 | ||||
| · probable | San Francisco, | $70.3M | 4 | 4 | ||||
Protego Biopharma, Inc. Company · Venture · matched Protego Biopharma · Series B Also on Private Equity | San Diego, | $130M | 2 | 8 | ||||
Alta Partners Management Corp. Firm · Venture · matched Alta Biopharma Partners · Exempt reporting adviser | · probable | San Francisco, | $10.6M | 3 | 4 | |||
| Fort Lee, | 2,579 | |||||||
| Berkeley Heights, | 1,211 | |||||||
| New York, | 646 | |||||||
| Cary, | 472 | |||||||
| Philadelphia, | 284 | |||||||
| San Diego, | 1 | 79 | ||||||
| Milford, | 300 | |||||||
| San Diego, | 229 | |||||||
| Denver, | 242 | |||||||
| Indianapolis, | 147 | |||||||
| 230 | ||||||||
| Farmingham, | 209 | |||||||
| Seattle, | 193 | |||||||
| Trevose, | 100 | |||||||
| Seattle, | 113 | |||||||
| Raleigh, | 101 | |||||||
| Elkridge, | 87 | |||||||
| Cambridge, | 112 | |||||||
| Warminster, | 109 | |||||||
| Houston, | 62 | |||||||
| San Francisco, | 3 | |||||||
Zenas BioPharma, Inc. Company · Venture · matched Zenas BioPharma (Cayman) Ltd · Form D equity offering Also on Private Equity | Waltham, | 1 | 2 | |||||
| Shorewood, | 2 | |||||||
| Northville, | 2 | |||||||
| New York, | 2 | |||||||
Cambrian BioPharma Inc Company · Venture · matched Cambrian BioPharma Inc. · Form D equity offering Also on Private Equity | New York, | 1 | 1 | |||||
| $125M | 1 | 8 | ||||||
Remiges Ventures, Inc. Firm · Venture · matched Remiges Biopharma Fund GP, Inc. · Exempt reporting adviser Also on RIA / Wealth Management | Seattle, | $175M | 17 | 3 | 19 | 2025 | ||
| Cambridge, | 1 | |||||||
Peptinovo Biopharma Inc. Company · Venture · matched Peptinovo Biopharma LLC · Form D equity offering | Ann Arbor, | 1 | ||||||
INCOG BioPharma Services, Inc. Company · Venture · matched COG BioPharma Services, Inc. · Form D equity offering | Fishers, | 1 | ||||||
| Chapel Hill, | 1 | |||||||
| Hayward, | 1 | |||||||
| Concord, | 1 | |||||||
| Boston, | 1 | |||||||
| Fort Lauderdale, | 1 | |||||||
| Boston, | 1 | |||||||
| Fremont, | 1 | |||||||
| Fort Collins, | 1 | |||||||
| Bedminster, | 1 | |||||||
| Golden, | 1 | |||||||
| $60.0M | 1 | 6 | ||||||
REDMILE BIOPHARMA INVESTMENTS III, L.P. Fund · RIA / Wealth · REDMILE GROUP Also on Private Equity, Venture Capital | $1.2B | 330 | 2021 | |||||
| $828M | 138 | 2019 |
Ranked by what the graph knows (size, observed deals, people, funds) unless you sort. Size is the best-evidenced figure for the row: AUM or regulatory AUM for firms and offices, close or reported gross asset value for funds, disclosed raised for companies. Click a class or a state in the table to filter by it. Counts are records per graph; with no graph selected, a firm that is on several graphs (matched by CRD, CIK, EIN or fund id, never by name) is listed once, with a dot for each graph.